First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors.

EClinicalMedicine · 2021 · PMC8040281 · PMID 33870151

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Sebum lipid analysis : Highly significant inhibition of sebum triglyceride production was seen after initiation of TVB-2640 as monotherapy and in combination.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.